Tag: neupogen filgrastim market growth

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Neupogen (filgrastim) Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The neupogen (filgrastim) market has experienced substantial growth in recent years. Its size is expected to increase from $1.4 million in 2025 to $1.48 million in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. Historically, this expansion has been driven by factors such as a rise in chemotherapy utilization, the considerable infection risk faced by neutropenic patients, the clinical endorsement of g-csf therapy, the prevalent hospital-centric model for cancer care, and the limited availability of early treatment choices.

The neupogen (filgrastim) market size is expected to show significant growth in the upcoming years. It is projected to achieve a value of $1.81 million by 2030, growing at a compound annual growth rate (CAGR) of 5.2%. This growth over the forecast period is attributed to several factors, including the rising incidence of cancer, increased adoption of biosimilar products, the expansion of outpatient oncology services, improved access to biologic therapies, and a strong focus on infection prevention. Major trends anticipated during this period encompass the growing application of supportive care in oncology, enhanced management of chemotherapy-induced neutropenia, broader adoption of biologic growth factors, a shift towards outpatient neutropenia treatment, and the expanding use of biosimilar alternatives.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=98729798&type=smp&name=Neupogen%20%28filgrastim%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Neupogen (filgrastim) Market Demand Drivers Opening New Revenue Streams

The neupogen (filgrastim) market is anticipated to expand due to the rising occurrence of diverse illnesses. These conditions represent bodily irregularities in structure or function, leading to distinct symptoms or site-specific impacts, frequently stemming from infections, genetic predispositions, environmental influences, or lifestyle decisions. The increasing incidence of these various health issues is fueled by factors such as demographic aging, inactive lifestyles, heightened pollution, inadequate nutritional practices, and the worldwide dissemination of infectious agents. Neupogen (filgrastim) helps manage issues arising from chemotherapy-induced neutropenia; it does this by encouraging neutrophil production, thus boosting the immune system’s capacity to fight infections in individuals with compromised immunity. Its role is crucial for lowering hospital admissions, controlling infection threats, and maintaining continuous cancer treatment schedules for patients receiving aggressive therapies. For example, data from April 2024 by Allergy UK, a national charity in the UK, reveals that over 21 million people in the UK suffer from allergies, a condition that was the most frequently reported chronic health issue in 2022. Projections further suggest that by 2026, half of Europe’s population will have experienced at least one allergy. Furthermore, in June 2022, Macmillan Cancer Support, a UK-based cancer charity, reported that 3 million individuals were living with cancer in 2022, with this figure expected to increase to almost 3.5 million by 2025 and 4 million by 2030 in the UK. Consequently, the growing prevalence of diverse diseases is a key factor stimulating the expansion of the neupogen (filgrastim) market.

Neupogen (filgrastim) Market Segments: Where Is Growth Concentrated?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Neupogen (filgrastim) Market Trends Powering Strategic Industry Growth

Companies active in the neupogen (filgrastim) market are prioritizing the creation of advanced filgrastim biosimilars, aiming to offer a more affordable and readily available option for managing neutropenia resulting from chemotherapy. These biosimilars are biological drugs designed to be highly similar to the original filgrastim (Neupogen) regarding their safety profile, effectiveness, and molecular structure. Their main application is to encourage neutrophil production in chemotherapy patients, thereby preventing neutropenia. An example of this trend occurred in September 2024 when Tanvex BioPharma, a U.S.-based biopharmaceutical firm, secured approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid). This product is a biosimilar directly referencing Amgen’s Neupogen. Nypozi was among three biosimilars granted FDA clearance on that particular day, contributing to the total of 55 biosimilars approved in the United States by June 2024. Its indication is for reducing the occurrence of infections, specifically those presenting as febrile neutropenia, in patients with non-myeloid malignancies undergoing treatment with myelosuppressive anticancer drugs.

Neupogen (filgrastim) Market Key Participants And Competitive Landscape

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

View The Full Neupogen (filgrastim) Market Report:

https://thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Neupogen (filgrastim) Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Neupogen (filgrastim) Market Growth From $ Billion In 2026 To $ Billion By 2030 At A CAGR Of %

The market for neupogen (filgrastim) has exhibited robust expansion in recent times. Its value is projected to rise from $1.4 million in 2025 to $1.48 million in 2026, reflecting a compound annual growth rate (CAGR) of 5.5%. This historic growth has been driven by factors such as increased chemotherapy usage, a heightened infection risk among neutropenic patients, clinically proven benefits of G-CSF therapy, cancer care concentrated in hospitals, and a scarcity of early-stage treatment alternatives.

Over the coming years, the neupogen (filgrastim) market is projected to experience robust expansion. By 2030, its value is anticipated to reach $1.81 million, reflecting a compound annual growth rate (CAGR) of 5.2%. This upward trajectory during the forecast period can be attributed to several factors: the rising prevalence of cancer, wider acceptance of biosimilars, growth in outpatient oncology services, improved patient access to biologic therapies, and a heightened emphasis on preventing infections. Key developments shaping this forecast include the growing integration of supportive care in oncology, better management of chemotherapy-induced neutropenia, broader utilization of biologic growth factors, a transition toward outpatient settings for neutropenia treatment, and an increasing reliance on biosimilar alternatives.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Neupogen (filgrastim) Market Growth Factors: Which Forces Are Supporting Market Expansion?

The expected rise in the frequency of diverse health conditions is anticipated to accelerate the expansion of the neupogen (filgrastim) market moving forward. Health conditions refer to irregularities in the body’s structure or function that generate distinct symptoms or impact particular sites, frequently stemming from infections, genetic factors, environmental influences, or lifestyle decisions. The growing occurrence of various health conditions is fueled by elements like aging populations, inactive lifestyles, increasing environmental contamination, unhealthy eating patterns, and the worldwide dispersion of infectious agents. Neupogen (filgrastim) mitigates the complications arising from chemotherapy-induced neutropenia by boosting neutrophil production, thereby strengthening the immune system’s capacity to fight infections in patients with compromised immunity. It plays a key role in lowering hospital admission rates, minimizing infection hazards, and facilitating uninterrupted cancer treatment schedules for individuals undergoing intensive therapies. For example, in April 2024, Allergy UK, a national charity based in the United Kingdom, reported that over 21 million individuals in the UK suffer from allergies, making it the most frequently cited chronic health issue in 2022, and forecasts suggest that by 2026, half of Europe’s population will have at least one allergy. Moreover, in June 2022, data released by Macmillan Cancer Support, a UK-based cancer charity, indicated that the number of people living with cancer reached 3 million in 2022, with projections showing an increase to nearly 3.5 million by 2025 and 4 million by 2030 within the UK. Consequently, the rising prevalence of various diseases is fueling the growth of the neupogen (filgrastim) market.

Government-led healthcare research and development efforts are set to drive the advancement of the neupogen (filgrastim) market in the future. Such government-led efforts encompass specific actions, programs, policies, or projects carried out by authorities at different tiers (local, regional, national, or global) to tackle particular challenges, realize certain objectives, or foster beneficial societal changes. Numerous government bodies are launching healthcare initiatives to support various aspects, including neupogen (filgrastim). As an example, in May 2023, the Department of Health and Social Care, a UK government authority, unveiled a $749.09 million (£650 million) “Life Sci for Growth” package aimed at boosting the life sciences industry. This package allocates $139.44 million (£121 million) to expedite commercial clinical trials, $177.47 million (£154 million) to enhance the UK Biobank’s capacities, and incentives up to $288.11 million (£250 million) to attract pension-fund investments into the sector. Hence, government initiatives for healthcare research and development are propelling the neupogen (filgrastim) market.

Neupogen (filgrastim) Market Segment Landscape: Which Areas Lead Market Development?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Neupogen (filgrastim) Market Industry Trends: What Changes Are Reshaping Demand?

Key players in the neupogen (filgrastim) market are placing a strong emphasis on creating novel products like filgrastim biosimilars, aiming to deliver cost-effective and accessible treatment options for chemotherapy-induced neutropenia. These filgrastim biosimilars are biologic agents designed to closely match the original filgrastim (Neupogen) in terms of safety, efficacy, and structural composition, and they are primarily utilized to boost neutrophil production in patients undergoing chemotherapy, thereby preventing neutropenia. A notable example occurred in September 2024 when Tanvex BioPharma, a biopharmaceutical firm based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar that references Amgen’s Neupogen. This product was among three biosimilars authorized by the FDA on that same date, adding to a total of 55 biosimilars that have been approved in the United States as of June 2024. Nypozi is indicated for reducing the occurrence of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies who are being treated with myelosuppressive anticancer drugs.

Neupogen (filgrastim) Market Industry Leaders And Market Competition

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Access The Complete Neupogen (filgrastim) Market Report:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Neupogen (filgrastim) Market Largest Region By Revenue And Market Share

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Neupogen (filgrastim) Market Through 2030?

The neupogen (filgrastim) market size has experienced robust growth in recent years. It is projected to expand from $1.4 million in 2025 to $1.48 million in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. The expansion witnessed during the historic period stems from increased chemotherapy utilization, the elevated risk of infection among neutropenic patients, the clinical validation of g-csf therapy, hospital-focused cancer care models, and limited early treatment alternatives.

The neupogen (filgrastim) market is anticipated to show significant expansion in the upcoming years. Its valuation is projected to reach $1.81 million by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. The growth during the forecast period stems from factors such as increasing cancer incidence, a broader adoption of biosimilars, the expansion of outpatient oncology services, enhanced access to biologic therapies, and a strong emphasis on infection prevention. Key trends expected over the forecast period include the rising application of supportive care in oncology, the expansion of management strategies for chemotherapy-induced neutropenia, increased uptake of biologic growth factors, a shift towards outpatient treatment for neutropenia, and the growing utilization of biosimilar alternatives.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

What Market Drivers Are Helping Shape The Neupogen (filgrastim) Market Expansion?

The neupogen (filgrastim) market is anticipated to expand due to the growing occurrence of diverse illnesses. Illnesses represent dysfunctions or structural irregularities within the body, manifesting distinct symptoms or impacting particular areas, frequently stemming from infections, genetic predispositions, environmental influences, or lifestyle choices. This surge in disease prevalence is fueled by an aging global populace, inactive lifestyles, heightened pollution, inadequate nutritional practices, and the worldwide dissemination of infectious agents. Neupogen (filgrastim) helps manage issues arising from chemotherapy-induced neutropenia by stimulating neutrophil generation, thus bolstering the immune system’s capacity to fight off infections in individuals with compromised immunity. Its role is crucial in lowering hospital admissions, mitigating infection dangers, and ensuring continuous cancer therapy for patients undergoing demanding treatments. For example, data from Allergy UK, a UK-based national charity, revealed in April 2024 that over 21 million people in the UK suffer from allergies, which was identified as the most common chronic health condition in 2022. Forecasts suggest that by 2026, half of Europe’s population will experience at least one allergy. Furthermore, in June 2022, Macmillan Cancer Support, a UK-based cancer charity, reported that 3 million individuals were living with cancer in the UK, a number expected to grow to nearly 3.5 million by 2025 and 4 million by 2030. Consequently, the rising incidence of diverse illnesses is fueling the expansion of the neupogen (filgrastim) market.

How Is The Neupogen (filgrastim) Market Distributed Across Key Segments?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Trends Are Expected To Shape The Neupogen (filgrastim) Market?

Companies operating primarily in the neupogen (filgrastim) market are increasingly concentrating on the development of novel filgrastim biosimilar products, aiming to offer an economical and accessible solution for managing chemotherapy-induced neutropenia. These filgrastim biosimilars are biological medicines designed to closely mirror the original filgrastim (Neupogen) in terms of safety, effectiveness, and molecular structure. Their primary function is to stimulate the creation of neutrophils in patients undergoing chemotherapy, thereby preventing neutropenia. For example, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical entity, secured approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar that references Amgen’s Neupogen. Nypozi was one of three biosimilars that received FDA clearance on that specific day, contributing to a cumulative total of 55 biosimilars approved in the United States by June 2024. This drug is prescribed to lessen the frequency of infection, particularly as it manifests in febrile neutropenia, for patients with non-myeloid malignancies receiving myelosuppressive anticancer agents.

Which Companies Form The Competitive Landscape Of The Neupogen (filgrastim) Market?

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Access The Complete Neupogen (filgrastim) Market Report:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

Which Regional Market Leads The Neupogen (filgrastim) Market?

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Neupogen (filgrastim) Market Progress Between 2026 And 2030?

The neupogen (filgrastim) market has experienced substantial growth in recent years. This market is projected to expand from $1.4 million in 2025 to $1.48 million in 2026, advancing at a compound annual growth rate (CAGR) of 5.5%. Historically, this expansion has been driven by factors including increased chemotherapy utilization, the elevated infection risk observed in neutropenic patients, the clinical validation of G-CSF therapy, hospital-centric cancer care models, and a scarcity of early treatment options.

The market size for neupogen (filgrastim) is anticipated to experience robust expansion over the coming years. It is projected to reach $1.81 million by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. This growth during the forecast period is attributable to several factors, including the rising incidence of cancer, increased adoption of biosimilars, the expansion of outpatient oncology services, enhanced access to biologic therapies, and a heightened focus on preventing infections. Key trends for the forecast period encompass a greater emphasis on supportive care in oncology, broadening of chemotherapy-induced neutropenia management, a surge in the embrace of biologic growth factors, a transition towards outpatient neutropenia treatment, and the expanding utilization of biosimilar alternatives.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

What Primary Drivers Are Shaping The Neupogen (filgrastim) Market?

The neupogen (filgrastim) market is anticipated to expand due to the growing occurrence of diverse illnesses. Illnesses represent dysfunctions or structural irregularities within the body, manifesting distinct symptoms or impacting particular areas, frequently stemming from infections, genetic predispositions, environmental influences, or lifestyle choices. This surge in disease prevalence is fueled by an aging global populace, inactive lifestyles, heightened pollution, inadequate nutritional practices, and the worldwide dissemination of infectious agents. Neupogen (filgrastim) helps manage issues arising from chemotherapy-induced neutropenia by stimulating neutrophil generation, thus bolstering the immune system’s capacity to fight off infections in individuals with compromised immunity. Its role is crucial in lowering hospital admissions, mitigating infection dangers, and ensuring continuous cancer therapy for patients undergoing demanding treatments. For example, data from Allergy UK, a UK-based national charity, revealed in April 2024 that over 21 million people in the UK suffer from allergies, which was identified as the most common chronic health condition in 2022. Forecasts suggest that by 2026, half of Europe’s population will experience at least one allergy. Furthermore, in June 2022, Macmillan Cancer Support, a UK-based cancer charity, reported that 3 million individuals were living with cancer in the UK, a number expected to grow to nearly 3.5 million by 2025 and 4 million by 2030. Consequently, the rising incidence of diverse illnesses is fueling the expansion of the neupogen (filgrastim) market.

What Are The Key Segment Divisions In The Neupogen (filgrastim) Market Segment Structure?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Trends Are Affecting The Direction Of The Neupogen (filgrastim) Market?

Companies active in the neupogen (filgrastim) market are increasingly prioritizing the development of innovative products as filgrastim biosimilars, aiming to offer a cost-effective and accessible treatment option for chemotherapy-induced neutropenia. Filgrastim biosimilars are biological medicines that closely mirror the original filgrastim (Neupogen) in terms of their safety, efficacy, and structure, primarily utilized to stimulate neutrophil production in patients undergoing chemotherapy to prevent neutropenia. For example, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar referencing Amgen’s Neupogen. Nypozi was one of three biosimilars cleared by the FDA on the same day, contributing to a total of 55 biosimilars approved in the United States as of June 2024. Its indicated use is to lower the incidence of infection, specifically febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.

Which Organizations Are Engaged In The Neupogen (filgrastim) Market?

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Get The Full Neupogen (filgrastim) Market Report:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

Which Region Holds The Highest Market Share In The Neupogen (filgrastim) Market?

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neupogen (filgrastim) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

Browse Through More Reports Similar to the Global Neupogen (filgrastim) Market 2026, By The Business Research Company

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Nebulizers Market 2026

https://www.thebusinessresearchcompany.com/report/nebulizers-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Neupogen (filgrastim) Market At The End Of The 2026–2030 Forecast Period?

The neupogen (filgrastim) market size has experienced robust growth in recent years. It is projected to increase from $1.4 million in 2025 to $1.48 million in 2026, at a compound annual growth rate (CAGR) of 5.5%. The expansion witnessed in the historic period is attributable to an increase in chemotherapy utilization, the high infection risk among neutropenic patients, the clinical validation of g-csf therapy, hospital-centered cancer care practices, and the limited availability of early treatment options.

The neupogen (filgrastim) market is anticipated to experience significant expansion over the coming years, with its size projected to reach $1.81 million by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. This expected growth throughout the forecast period is primarily attributed to factors such as the increasing incidence of cancer, the wider adoption of biosimilars, the expansion of outpatient oncology services, improved access to biologic therapies, and a concentrated focus on infection prevention. Additionally, major trends during this period are expected to include the rising implementation of supportive care in oncology, the broadened management of chemotherapy-induced neutropenia, increased uptake of biologic growth factors, a shift towards outpatient neutropenia treatment, and the growing availability and use of biosimilar alternatives.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

What Primary Drivers Are Shaping The Development Of The Neupogen (filgrastim) Market?

An escalating incidence of various diseases is anticipated to fuel the expansion of the neupogen (filgrastim) market moving forward. Diseases represent functional or structural irregularities in the body, manifesting distinct symptoms or affecting specific areas, often stemming from infections, genetic predispositions, environmental factors, or lifestyle choices. The rising occurrence of diverse diseases is propelled by factors such as aging demographics, sedentary lifestyles, increasing pollution levels, suboptimal dietary habits, and the global dissemination of infectious pathogens. Neupogen (filgrastim) effectively manages the complications of neutropenia induced by chemotherapy by stimulating the creation of neutrophils, thereby bolstering the immune system’s capacity to combat infections in patients with compromised immunity. Its role is vital in reducing hospitalizations, mitigating infection risks, and facilitating continuous cancer treatment plans for individuals undergoing intensive therapies. For instance, in April 2024, Allergy UK, a UK-based national charity, reported that over 21 million people in the UK are affected by allergies, which became the most frequently cited chronic health condition in 2022, with forecasts indicating that by 2026, half of Europe’s population will experience at least one allergy. Additionally, in June 2022, data from Macmillan Cancer Support, a UK-based cancer charity, showed that the number of individuals living with cancer reached 3 million in 2022 and is projected to increase to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Consequently, the increasing prevalence of various diseases is a significant driver for the growth of the neupogen (filgrastim) market.

What Segment Types Make Up The Neupogen (filgrastim) Market?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Market Trends Are Creating New Opportunities In The Neupogen (filgrastim) Market?

Companies operating within the neupogen (filgrastim) market are increasingly focused on developing innovative filgrastim biosimilar products to offer a cost-effective and accessible option for treating chemotherapy-induced neutropenia. Filgrastim biosimilars are biological medications that closely mirror the original filgrastim (Neupogen) regarding safety, efficacy, and structure, primarily utilized to stimulate neutrophil production in patients receiving chemotherapy to prevent neutropenia. For instance, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar referencing Amgen’s Neupogen. Nypozi was one of three biosimilars cleared by the FDA on the same day, contributing to a cumulative total of 55 biosimilars approved in the United States as of June 2024. It is indicated for lowering the incidence of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anticancer drugs.

Who Are The Key Players Driving Competition In The Neupogen (filgrastim) Market?

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Read the full neupogen (filgrastim) market report here:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

How Does The Neupogen (filgrastim) Market Perform Across Major Global Regions?

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neupogen (filgrastim) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp

Browse Through More Reports Similar to the Global Neupogen (filgrastim) Market 2026, By The Business Research Company

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Nebulizers Market 2026

https://www.thebusinessresearchcompany.com/report/nebulizers-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Neupogen (filgrastim) Market At The End Of The 2026–2030 Forecast Period?

The neupogen (filgrastim) market size has experienced robust growth in recent years. It is projected to increase from $1.4 million in 2025 to $1.48 million in 2026, at a compound annual growth rate (CAGR) of 5.5%. The expansion witnessed in the historic period is attributable to an increase in chemotherapy utilization, the high infection risk among neutropenic patients, the clinical validation of g-csf therapy, hospital-centered cancer care practices, and the limited availability of early treatment options.

The neupogen (filgrastim) market is anticipated to experience significant expansion over the coming years, with its size projected to reach $1.81 million by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. This expected growth throughout the forecast period is primarily attributed to factors such as the increasing incidence of cancer, the wider adoption of biosimilars, the expansion of outpatient oncology services, improved access to biologic therapies, and a concentrated focus on infection prevention. Additionally, major trends during this period are expected to include the rising implementation of supportive care in oncology, the broadened management of chemotherapy-induced neutropenia, increased uptake of biologic growth factors, a shift towards outpatient neutropenia treatment, and the growing availability and use of biosimilar alternatives.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

What Primary Drivers Are Shaping The Development Of The Neupogen (filgrastim) Market?

An escalating incidence of various diseases is anticipated to fuel the expansion of the neupogen (filgrastim) market moving forward. Diseases represent functional or structural irregularities in the body, manifesting distinct symptoms or affecting specific areas, often stemming from infections, genetic predispositions, environmental factors, or lifestyle choices. The rising occurrence of diverse diseases is propelled by factors such as aging demographics, sedentary lifestyles, increasing pollution levels, suboptimal dietary habits, and the global dissemination of infectious pathogens. Neupogen (filgrastim) effectively manages the complications of neutropenia induced by chemotherapy by stimulating the creation of neutrophils, thereby bolstering the immune system’s capacity to combat infections in patients with compromised immunity. Its role is vital in reducing hospitalizations, mitigating infection risks, and facilitating continuous cancer treatment plans for individuals undergoing intensive therapies. For instance, in April 2024, Allergy UK, a UK-based national charity, reported that over 21 million people in the UK are affected by allergies, which became the most frequently cited chronic health condition in 2022, with forecasts indicating that by 2026, half of Europe’s population will experience at least one allergy. Additionally, in June 2022, data from Macmillan Cancer Support, a UK-based cancer charity, showed that the number of individuals living with cancer reached 3 million in 2022 and is projected to increase to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Consequently, the increasing prevalence of various diseases is a significant driver for the growth of the neupogen (filgrastim) market.

What Segment Types Make Up The Neupogen (filgrastim) Market?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Market Trends Are Creating New Opportunities In The Neupogen (filgrastim) Market?

Companies operating within the neupogen (filgrastim) market are increasingly focused on developing innovative filgrastim biosimilar products to offer a cost-effective and accessible option for treating chemotherapy-induced neutropenia. Filgrastim biosimilars are biological medications that closely mirror the original filgrastim (Neupogen) regarding safety, efficacy, and structure, primarily utilized to stimulate neutrophil production in patients receiving chemotherapy to prevent neutropenia. For instance, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar referencing Amgen’s Neupogen. Nypozi was one of three biosimilars cleared by the FDA on the same day, contributing to a cumulative total of 55 biosimilars approved in the United States as of June 2024. It is indicated for lowering the incidence of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anticancer drugs.

Who Are The Key Players Driving Competition In The Neupogen (filgrastim) Market?

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Read the full neupogen (filgrastim) market report here:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

How Does The Neupogen (filgrastim) Market Perform Across Major Global Regions?

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neupogen (filgrastim) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp

Browse Through More Reports Similar to the Global Neupogen (filgrastim) Market 2026, By The Business Research Company

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Nebulizers Market 2026

https://www.thebusinessresearchcompany.com/report/nebulizers-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Neupogen (filgrastim) Market At The End Of The 2026–2030 Forecast Period?

The neupogen (filgrastim) market size has experienced robust growth in recent years. It is projected to increase from $1.4 million in 2025 to $1.48 million in 2026, at a compound annual growth rate (CAGR) of 5.5%. The expansion witnessed in the historic period is attributable to an increase in chemotherapy utilization, the high infection risk among neutropenic patients, the clinical validation of g-csf therapy, hospital-centered cancer care practices, and the limited availability of early treatment options.

The neupogen (filgrastim) market is anticipated to experience significant expansion over the coming years, with its size projected to reach $1.81 million by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. This expected growth throughout the forecast period is primarily attributed to factors such as the increasing incidence of cancer, the wider adoption of biosimilars, the expansion of outpatient oncology services, improved access to biologic therapies, and a concentrated focus on infection prevention. Additionally, major trends during this period are expected to include the rising implementation of supportive care in oncology, the broadened management of chemotherapy-induced neutropenia, increased uptake of biologic growth factors, a shift towards outpatient neutropenia treatment, and the growing availability and use of biosimilar alternatives.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

What Primary Drivers Are Shaping The Development Of The Neupogen (filgrastim) Market?

An escalating incidence of various diseases is anticipated to fuel the expansion of the neupogen (filgrastim) market moving forward. Diseases represent functional or structural irregularities in the body, manifesting distinct symptoms or affecting specific areas, often stemming from infections, genetic predispositions, environmental factors, or lifestyle choices. The rising occurrence of diverse diseases is propelled by factors such as aging demographics, sedentary lifestyles, increasing pollution levels, suboptimal dietary habits, and the global dissemination of infectious pathogens. Neupogen (filgrastim) effectively manages the complications of neutropenia induced by chemotherapy by stimulating the creation of neutrophils, thereby bolstering the immune system’s capacity to combat infections in patients with compromised immunity. Its role is vital in reducing hospitalizations, mitigating infection risks, and facilitating continuous cancer treatment plans for individuals undergoing intensive therapies. For instance, in April 2024, Allergy UK, a UK-based national charity, reported that over 21 million people in the UK are affected by allergies, which became the most frequently cited chronic health condition in 2022, with forecasts indicating that by 2026, half of Europe’s population will experience at least one allergy. Additionally, in June 2022, data from Macmillan Cancer Support, a UK-based cancer charity, showed that the number of individuals living with cancer reached 3 million in 2022 and is projected to increase to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Consequently, the increasing prevalence of various diseases is a significant driver for the growth of the neupogen (filgrastim) market.

What Segment Types Make Up The Neupogen (filgrastim) Market?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Market Trends Are Creating New Opportunities In The Neupogen (filgrastim) Market?

Companies operating within the neupogen (filgrastim) market are increasingly focused on developing innovative filgrastim biosimilar products to offer a cost-effective and accessible option for treating chemotherapy-induced neutropenia. Filgrastim biosimilars are biological medications that closely mirror the original filgrastim (Neupogen) regarding safety, efficacy, and structure, primarily utilized to stimulate neutrophil production in patients receiving chemotherapy to prevent neutropenia. For instance, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar referencing Amgen’s Neupogen. Nypozi was one of three biosimilars cleared by the FDA on the same day, contributing to a cumulative total of 55 biosimilars approved in the United States as of June 2024. It is indicated for lowering the incidence of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anticancer drugs.

Who Are The Key Players Driving Competition In The Neupogen (filgrastim) Market?

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Read the full neupogen (filgrastim) market report here:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

How Does The Neupogen (filgrastim) Market Perform Across Major Global Regions?

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neupogen (filgrastim) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp

Browse Through More Reports Similar to the Global Neupogen (filgrastim) Market 2026, By The Business Research Company

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Nebulizers Market 2026

https://www.thebusinessresearchcompany.com/report/nebulizers-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the neupogen (filgrastim) market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Neupogen (filgrastim) Market in 2030?

The neupogen (filgrastim) market has experienced robust growth in recent years. It is projected to increase from $1.4 million in 2025 to $1.48 million in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This historical expansion can be attributed to factors such as increased chemotherapy utilization, the high infection risk faced by neutropenic patients, the clinical validation of g-csf therapy, hospital-centered cancer care approaches, and the limited availability of early treatment options.

The market size for neupogen (filgrastim) is anticipated to experience substantial growth in the coming years. It is projected to expand to $1.81 million by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. This expected growth during the forecast period stems from factors such as increasing instances of cancer, wider adoption of biosimilars, an increase in outpatient oncology services, improved availability of biologic therapies, and a focus on preventing infections. Prominent trends throughout the forecast period include a rising emphasis on supportive care in oncology, the expansion of management strategies for chemotherapy-induced neutropenia, greater acceptance of biologic growth factors, a shift towards outpatient neutropenia treatment, and the increasing use of biosimilar alternatives.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

What Drivers Are Influencing Production Trends In The Neupogen (filgrastim) Market?

The expanding occurrence of diverse illnesses is anticipated to fuel the future expansion of the neupogen (filgrastim) market. These conditions represent bodily irregularities in structure or function, leading to distinct symptoms or impacting particular areas, frequently resulting from infections, genetic predispositions, environmental elements, or lifestyle decisions. The growing frequency of these ailments stems from contributing factors like demographic aging, inactive lifestyles, heightened pollution, inadequate diets, and the worldwide dissemination of infectious agents. Neupogen (filgrastim) tackles issues arising from chemotherapy-induced neutropenia by boosting neutrophil production, thus strengthening the immune system’s capacity to fight infections in individuals with compromised immunity. This treatment plays a vital role in lowering hospitalization figures, mitigating infection dangers, and enabling continuous cancer treatment plans for patients undergoing rigorous therapies. For example, data from Allergy UK, a national charity in the UK, indicated in April 2024 that over 21 million people in the UK suffer from allergies, marking it as the most common chronic health condition in 2022, with forecasts suggesting that by 2026, half of Europe’s population will have experienced at least one allergy. Furthermore, in June 2022, Macmillan Cancer Support, a UK-based cancer charity, reported that 3 million individuals were living with cancer in the UK, a number expected to increase to almost 3.5 million by 2025 and 4 million by 2030. Consequently, the rising occurrence of diverse illnesses is a key factor propelling the expansion of the neupogen (filgrastim) market.

Which Segments Are Gaining Traction In The Neupogen (filgrastim) Market?

The neupogen (filgrastim) market covered in this report is segmented –

1) By Drug Type: Biologic, Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Competitive Trends Are Impacting The Structure Of The Neupogen (filgrastim) Market?

Companies operating in the neupogen (filgrastim) market are increasingly prioritizing the development of innovative filgrastim biosimilar products, aiming to offer a cost-effective and accessible solution for managing chemotherapy-induced neutropenia. Filgrastim biosimilars are biological medicines designed to closely resemble the original filgrastim (Neupogen) in terms of safety, efficacy, and structure, and are primarily used to stimulate neutrophil production in patients undergoing chemotherapy to prevent neutropenia. For example, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar referencing Amgen’s Neupogen. Nypozi was one of three biosimilars cleared by the FDA on the same day, contributing to a total of 55 biosimilars approved in the United States as of June 2024. It is indicated for reducing the incidence of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anticancer drugs.

Who Are The Core Companies Influencing Trends In The Neupogen (filgrastim) Market?

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

Which Regions Are Projected To Dominate The Neupogen (filgrastim) Market In The Coming Years?

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neupogen (filgrastim) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp

Browse Through More Reports Similar to the Global Neupogen (filgrastim) Market 2026, By The Business Research Company

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Nebulizers Market 2026

https://www.thebusinessresearchcompany.com/report/nebulizers-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Neupogen (filgrastim) Market Growth Performance Trended Historically, And What Lies Ahead?

Recent years have seen a robust increase in the market size of neupogen (filgrastim). Projections put its growth from $1,330.69 million in 2024 to a massive $1,404.70 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.6%. This historic growth trajectory is the result of factors such as the rise in cancer cases, heightened awareness about neutropenia induced by chemotherapy, advancements in healthcare facilities, expedited approvals for Neupogen biosimilars, and an overall increase in global healthcare expenditure.

What Is the Forecast for the Neupogen (filgrastim) Market Size Through 2029?

Anticipations suggest a robust increase in the market size of Neupogen (Filgrastim) in the coming years, expected to expand to $1,727.05 million by 2029 at a compound annual growth rate (CAGR) of 5.3%. Multiple factors contributing to this projected growth include heightening demand for affordable neutropenia treatments, blossoming healthcare infrastructure in emerging economies, escalated governmental backing for biosimilar inclusion, enhanced emphasis on individualized medicine, and an aging demographic. Upcoming market trends encompass escalated investment for R&D in biosimilars, innovations in neutropenia drug delivery methods, growing collaborations for oncology drug marketing, intensified focus on patient-centric affordability schemes, and the creation of new G-CSF products.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

What are the Key Market Players in Neupogen (filgrastim) Market and How They’re Evolving?

Major companies operating in the neupogen (filgrastim) market include Amgen Inc.

What Are the Primary Growth Drivers in the Neupogen (filgrastim) Market?

An escalation in the frequency of diverse diseases is anticipated to be a key driver for the expansion of the neupogen (filgrastim) market. Diseases, which are essentially human body abnormalities, often result from infection, hereditary factors, environmental aspects, or lifestyle preferences, leading to unique symptoms and location-based effects. The escalating frequency of such diseases is fueled by elements like ageing demographics, inactive lifestyles, high pollution levels, poor nutrition habits and the worldwide propagation of infectious pathogens. Neupogen (filgrastim) aids in combatting the complications arising from chemotherapy-driven neutropenia through increased production of neutrophils, boosting the immune response against infections particularly in patients with weakened immunity. It plays a crucial role in reducing hospital stays, managing the risk of infection and ensuring continuous cancer care programmes for patients subjected to intensive treatments. For instance, Allergy UK, a UK-based national charity, reported in April 2024 that allergies, which became the most frequently reported chronic ailment in 2022, affected over 21 million individuals in the UK. By 2026, it is projected that at least one allergy would affect half of Europe’s population. Additionally, in June 2022, according to data published by Macmillan Cancer Support, a UK-based cancer charity, the number of cancer patients was 3 million in 2022 with predictions of nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Thus, the escalating frequency of diverse diseases drives the expansion of the neupogen (filgrastim) market. Government Healthcare Research and Development Initiatives Fuel Growth for Neupogen (filgrastim)

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp

What Are the Leading Segments in the Global Neupogen (filgrastim) Industry?

The neupogen (filgrastim)market covered in this report is segmented –

1) By Drug Type: Biologic; Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

What Are the Key Market Trends in the Neupogen (filgrastim) Industry?

A primary trend taking place in the neupogen (filgrastim) market involves a concentration on the development of innovative goods that serve as filgrastim biosimilar alternatives. These alternatives offer a cost-saving and accessible option for handling chemotherapy-induced neutropenia. Biologic medications, such as filgrastim biosimilar solutions, closely resemble their original version, Neupogen, offering similar safety, efficacy, and structure, and are used predominantly to kindle neutrophil production in chemotherapy patients to prevent neutropenia. For example, in November 2022, Releuko (filgrastim-ayow), a biosimilar of Neupogen (filgrastim), was introduced to the American market by Amneal Pharmaceuticals and Kashiv Biosciences, both US-based companies. Releuko provides both intravenous and subcutaneous options, in single-dose vials and prefilled syringes, giving healthcare providers a choice of dosing. This product holds significance for offering a cost-effective solution for chemotherapy-induced neutropenia, hence increasing the availability of critical oncology care and meeting the surge in demand for biosimilars in the market.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

What Is the Regional Outlook for the Neupogen (filgrastim) Market?

North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19910

This Report Delivers Insight On:

1. How big is the neupogen (filgrastim) market, and how is it changing globally?

2. Who are the major companies in the neupogen (filgrastim) market, and how are they performing?

3. What are the key opportunities and risks in the neupogen (filgrastim) market right now?

4. Which products or customer segments are growing the most in the neupogen (filgrastim) market?

5. What factors are helping or slowing down the growth of the neupogen (filgrastim) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the neupogen (filgrastim) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Projected CAGR for the Neupogen (filgrastim) Market Size from 2025 to 2034?

The market for neupogen (filgrastim) has significantly expanded in past years and is projected to continue this trend, with its value expected to increase from $1,330.69 million in 2024 to $1,404.70 billion in 2025, representing a compound annual growth rate (CAGR) of 5.6%. This upward trend in the historical timeline can be linked to a surge in cancer cases, heightened understanding of chemotherapy-induced neutropenia, enhancements in healthcare facilities, early green light for Neupogen biosimilars, and an uptick in worldwide healthcare expenditure.

There is a prediction for a significant increase in the market value of neupogen (filgrastim) in the coming years. By 2029, the market is projected to reach $1,727.05 million, expanding at a compound annual growth rate (CAGR) of 5.3%. This projected increase over the forecast period can be linked to factors such as growing requirement for cost-effective treatments for neutropenia, broader healthcare coverage in fast-growing markets, enhanced governmental backing for biosimilar infiltration, reinforced emphasis on personalized medicine, and an aging demographic. Forecast period trends include escalated investment in research and development for biosimilars, progression in neutropenia treatment drug delivery systems, increased alliances for cancer drug marketing, amplified focus on patient cost relief programs, and the emergence of new-generation G-CSF products.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

Which Factors and External Forces Are Driving Demand in the Neupogen (filgrastim) Market?

The surge of various illnesses is anticipated to fuel the neupogen (filgrastim) market’s expansion. These diseases, caused by infections, inherited traits, environmental elements, or lifestyle decisions, introduce abnormalities in the body’s structure or function, leading to specific symptoms or impacting specific locations. The growing prevalence of these diseases can be attributed to aging populations, inactive lifestyles, increasing pollution, unhealthy diets, and the worldwide dissemination of infectious pathogens. Neupogen (filgrastim) helps manage chemotherapy-induced neutropenia complications by boosting neutrophil formation and strengthening the immune system’s ability to fight off infections in patients with compromised immunity. This makes it key in reducing hospitalization rates, managing infection risks, and maintaining persistent cancer treatment plans for patients receiving intensive therapies. For example, Allergy UK reported in April 2024 that allergies affect more than 21 million UK residents, making it the most frequently reported chronic health issue in 2022. Predictions suggest that half of Europe’s population will have at least one allergy by 2026. Furthermore, Macmillan Cancer Support reported in June 2022 that 3 million people were living with cancer in 2022 in the UK, a figure expected to rise approximately to 3.5 million by 2025 and 4 million by 2030. Hence, the rising occurrence of various diseases propels the growth of the neupogen (filgrastim) market. Government-led healthcare research and development programs are expected to further fuel the expansion of the neupogen (filgrastim) market. These initiatives undertaken by authorities at various levels (local to international) aim to address specific issues, achieve particular objectives, or bring about positive changes in society. Many authorities are spearheading healthcare initiatives that include neupogen (filgrastim) support. As per the Department of Health and Social Care based in the UK in 2022, the UK government disclosed £260 million (US $270.65 million) funding to stimulate healthcare research and manufacturing. This was pledged by BEIS and DHSC to aid NHS-led health research into diagnostics and treatment via new privacy-conserving platforms and clinical research services and £60 million (US $63.60 million) was committed to enhance life sciences manufacturing in the UK. Hence, government-led healthcare research and development initiatives stimulate the neupogen (filgrastim) market.

Which Segments in the Neupogen (filgrastim) Offer the Most Growth?

The neupogen (filgrastim)market covered in this report is segmented –

1) By Drug Type: Biologic; Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp

What Are the Fastest-Growing Geographies in the Neupogen (filgrastim) Market?

North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theNeupogen (filgrastim) Market’s Growth?

The principal trend in the Neupogen (filgrastim) market is concentrated on developing innovative filgrastim biosimilar products as an efficient and budget-friendly substitute for the treatment of chemotherapy-induced neutropenia. These biosimilar solutions are biological medications that strongly mirror the original filgrastim (Neupogen) in safety, efficacy, and structure. Their principal purpose is to stimulate neutrophil production in patients receiving chemotherapy to prevent neutropenia. For example, Amneal Pharmaceuticals and Kashiv Biosciences, both US-centric companies, introduced Releuko (filgrastim-ayow), a biosimilar referencing Neupogen (filgrastim), to the US market in November 2022. Available in single-dose vials and prefilled syringes for intravenous and subcutaneous administrations, Releuko provides dosage flexibility to healthcare providers. Its importance lies in providing a budget-friendly therapeutic option for chemotherapy-induced neutropenia, increasing the accessibility of vital oncology care, and meeting the growing demand for biosimilars in the market.

View the full report here:

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

What Are the Key Elements That Define the Neupogen (filgrastim) Market?

Neupogen (filgrastim) is a recombinant granulocyte colony-stimulating factor (G-CSF) that stimulates the production of white blood cells in the bone marrow. It is used to prevent infection in patients with neutropenia caused by chemotherapy, bone marrow transplantation, or certain medical conditions.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19910

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model